one hundred fifty-six patients with presumed or documented abdominal infections were treated with amikacin/metronidazole/placebo ( group 1 , 56 patients ) , amikacin/clindamycin/placebo ( group 2 , 57 patients ) , or amikacin/clindamycin/ampicillin ( group 3 , 43 patients ) to determine both the therapeutic efficacy of the various regimens and the type of complications due to clostridium difficile .
C1112209
abdominal infections
C0002499
amikacin